Naringenin Decreases Invasiveness and Metastasis by Inhibiting TGF-β-Induced Epithelial to Mesenchymal Transition in Pancreatic Cancer Cells

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Lou, Changjie ^a,b   Zhang, Fayun ^b   Yang, Ming ^a   Zhao, Juan ^a   Zeng, Wenfeng ^b   Fang, Xiaocui ^b   Zhang, Yanqiao ^a   Zhang, Chunling ^b   Liang, Wei ^b  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b INSTITUTE OF BIOPHYSICS   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE A; GELATINASE B; GEMCITABINE; NARINGENIN; NERVE CELL ADHESION MOLECULE; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; VIMENTIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER INVASION; CELL MOTILITY; CONTROLLED STUDY; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; HUMAN; HUMAN CELL; MARKER GENE; METASTASIS; METASTASIS INHIBITION; MIGRATION INHIBITION; PANCREAS CANCER; PROTEIN EXPRESSION; UPREGULATION;

APOPTOSIS; BLOTTING, WESTERN; CELL MOVEMENT; CELL PROLIFERATION; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; EPITHELIAL-MESENCHYMAL TRANSITION; ESTROGEN ANTAGONISTS; FLAVANONES; HUMANS; NEOPLASM INVASIVENESS; PANCREATIC NEOPLASMS; PHOSPHORYLATION; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSFORMING GROWTH FACTOR BETA; TUMOR CELLS, CULTURED; WOUND HEALING;

EID: 84871591193     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0050956     Document Type: Article

References (38)

1. Jemal A, Siegel R, Xu J, Ward E, (2010) Cancer statistics. CA Cancer J Clin 60: 277-300.
2. Thomas H, Coley HM, (2003) Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting P-glycoprotein. Cancer Control 10 (2) (): 159-65.
3. Varadhachary GR, Tamm EP, Abbruzzese JL, Xiong HQ, Crane CH, et al. (2006) Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol 13: 1035-1046.
4. Furukawa H, Okada S, Saisho H, Ariyama J, Karasawa E, et al. (1996) Clinicopathologic features of small pancreatic adenocarcinoma, A collective study. Cancer 78: 986-990.
5. Vincent A, Herman J, Schulick R, Hruban RH, Goggins M, (2004) Pancreatic cancer,. Lancet 363: 1049-1057.
6. Kang Y, Massague J, (2004) Epithelial-mesenchymal transitions: twist in development and metastasis. Cell 118: 277-279.
7. Nakajima S, Doi R, Toyoda E, (2004) N-cadherin expression and epithelial-mesenchymal transition in pancreatic carcinoma. Clin Cancer Res 10: 4125-4133.
8. Arumugam T, Ramachandran V, Fournier KF, Wang H, Marquis L, et al. (2009) Epithelial to Mesenchymal Transition Contributes to Drug Resistance in Pancreatic Cancer. Cancer Res 69: 5820-5828.
9. Ellenrieder V, Hendler SF, Ruhland C, Boeck W, Adler G, et al. (2001) TGF-beta-induced invasiveness of pancreatic cancer cells is mediated by matrix metalloproteinase-2 and the urokinase plasminogen activator system. Int J Cancer 93: 204-211.
10. Vandewalle C, Comijn J, Craene BD, Vermassen P, Bruyneel E, et al. (2005) SIP1/ ZEB2 induces EMT by repressing genes of different epithelial cell-cell junctions. Nucleic Acids Res 33: 6566-6578.
11. Thiery JP, Acloque H, Huang RY, Nieto MA, (2009) Epithelial-mesenchymal transitions in development and disease. Cell 139: 871-890.
12. Wang Z, Li Y, Ahmad A, Banerjee S, Azmi AS, et al. (2011) Pancreatic cancer: understanding and overcoming chemoresistance. Nat Rev Gastroenterol Hepatol 8: 27-33.
13. Oft M, Peli J, Rudaz C, Schwarz H, Beug H, et al. (1996) TGF-beta1 and Ha-Ras collaborate in modulating the phenotypic plasticity and invasiveness of epithelial tumor cells. Genes Dev 10: 2462-2477.
14. Yin T, Wang C, Liu T, Zhao G, Zhou F, (2006) Implication of EMT induced by TGF-beta1 in pancreatic cancer. J Huazhong Univ Sci Technolog Med Sci 26: 700-702.
15. Ellenrieder V, Hendler SF, Boeck W, Seufferlein T, Menke A, et al. (2001) Transforming growth factor beta1 treatment leads to an epithelial-mesenchymal transdifferentiation of pancreatic cancer cells requiring extracellular signal-regulated kinase 2 activation. Cancer Res 61: 4222-4228.
16. Levy L, Hill CS, (2006) Alterations in components of the TGF-beta superfamily signaling pathways in human cancer. Cytokine Growth Factor Rev 17: 41-58.
17. Yingling JM, Blanchard KL, Sawyer JS, (2004) Development of TGF-beta signalling inhibitors for cancer therapy. Nat Rev Drug Discovery 3 (12) (): 1011-1022.
18. Flavell RA, Sanjabi S, Wrzesinski SH, Licona-Limón P, (2010) The polarization of immune cells in the tumour environment by TGFbeta. Nat Rev Immunol 10 (8) (): 554-567.
19. Hau P, Jachimczak P, Schlingensiepen R, Schulmeyer F, Jauch T, et al. (2007) Inhibition of TGF-beta2 with AP 12009 in recurrent malignant gliomas: from preclinical to phase I/II studies. Oligonucleotides 17 (2) (): 201-212.
20. Fakhrai H, Mantil JC, Liu L, Nicholson GL, Murphy-Satter CS, et al. (2006) Phase I clinical trial of a TGF-beta antisense-modified tumor cell vaccine in patients with advanced glioma. Cancer Gene Ther 13 (12) (): 1052-1060.
21. Callahan JF, Burgess JL, Fornwald JA, Gaster LM, Harling JD, et al. (2002) Identification of novel inhibitors of the transforming growth factor beta1 (TGF-beta1) type 1 receptor (ALK5). J Med Chem 45 (5) (): 999-1001.
22. Du G, Jin L, Han X, Song Z, Zhang H, et al. (2009) Naringenin: a potential immunomodulator for inhibiting lung fibrosis and metastasis. Cancer Res 69: 3205-3212.
23. Yang Y, Xu Y, Xia T, Chen F, Zhang C, et al. (2011) A single-molecule study of the inhibition effect of Naringenin on transforming growth factor-β ligand-receptor binding. Chem Commun (Camb) 47: 5440-5442.
24. Liu X, Wang W, Hu H, Tang N, Zhang C, et al. (2006) Smad3 specific inhibitor, naringenin, decreases the expression of extracellular matrix induced by TGF-beta1 in cultured rat hepatic stellate cells. Pharm Res 23: 82-89.
25. Zhang FY, Du GJ, Zhang L, Zhang CL, Liang W, et al. (2009) Narigenin enhances the anti-tumor effect of doxorubicin through selectively inhibiting the activity of multidrug resistance-associated proteins but not p-glycoprotein. Pharm Res 26: 914-925.
26. Banerjee S, Kong D, Azmi AS, Wang Z, Ahmad A, et al. (2011) Restoring sensitivity to oxaliplatin by a novel approach in gemcitabin-resistant pancreatic cancer cells in vitro and in vivo. Int J Cancer 128: 1240-1250.
27. Valcourt U, Kowanetz M, Niimi H, Heldin CH, Moustakas A, (2005) TGF-beta and the Smad signaling pathway support transcriptomic reprogramming during epithelial-mesenchymal cell transition. Mol Biol Cell 16 (4) (): 1987-2002.
28. Lim H, Park H, Kim HP, (2011) Effects of flavonoids on matrix metalloproteinase-13 expression of interleukin-1β-treated articular chondrocytes and their cellular mechanisms: inhibition of c-Fos/AP-1 and JAK/STAT signaling pathways. J pharmacol Sci 116: 221-231.
29. Jeong JH, An JY, Kwon YT, Rhee JG, Lee YJ, (2009) Effects of low dose quercetin: cancer cell-specific inhibition of cell cycle progression. J Cell Biochem 106: 73-82.
30. Laping NJ, Grygielko E, Matur A, Butter S, Bomberger J, et al. (2002) Inhibition of transforming growth factor(TGF)-beta1-induced extracellular matrix with a novel inhibitor of the TGF-beta type I receptor kinase activity: SB-431542. Mol Pharmacol 62: 58-64.
31. Shin JA, Hong OK, Lee HJ, Jeon SY, Kim JW, et al. (2011) Transforming growth factor-β induces epithelial to mesenchymal transition and suppression the proliferation and transdifferentiation of cultured human pancreatic duct cells. J Cell Biochem 112: 179-188.
32. Ellenrieder V, Hendler SF, Boeck W, Seufferlein T, Menke A, et al. (2001) Transforming Growth Factor-beta1 treatment leads to an epithelial-mesenchymal transdifferentiation of pancreatic cancer cells requiring extrancellular signal-regulated kinase 2 activation. Cancer Res 61: 4222-4228.
33. Duarte N, Lage H, Abrantes M, Ferreira MJ, (2010) Phenolic compounds as selective antineoplasic agents against multidrug-resistan human cancer cells. Planta Med 76: 975-980.
34. Tang L, Yamashita M, Coussens NP, Tang Y, Wang X, et al. (2011) Ablation of Smurf2 reveals an inhibition in TGF-β signalling through multiple mono- ubiquitination of Smad3. EMBO J 30: 4777-4789.
35. Qin L, Jin L, Lu L, Lu X, Zhang C, et al. (2011) Naringenin reduces lung metastasis in a breast cancer resection model. Protein Cell 2 (6) (): 507-516.
36. Halder SK, Beauchamp RD, Datta PK, (2005) A specific inhibitor of TGF-beta receptor kinase, SB-431542, as a potent antitumor agent for human cancer. Neoplasia 7: 509-521.
37. Mosmann T, (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol. Methods 65: 55-63.
38. Labbe E, Silvestri C, Hoodless PA, Wrana JL, Attisano L, (1998) Smad2 and Smad3 positively and negatively regulate TGF beta-dependent transcription through the forkhead DNA-binding protein FAST2. Mol Cell 2: 109-20.